Your browser doesn't support javascript.
loading
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Assenat, Eric; Mineur, Laurent; Mollevi, Caroline; Lopez-Crapez, Evelyne; Lombard-Bohas, Catherine; Samalin, Emmanuelle; Portales, Fabienne; Walter, Thomas; de Forges, Hélène; Dupuy, Marie; Boissière-Michot, Florence; Ho-Pun-Cheung, Alexandre; Ychou, Marc; Mazard, Thibaut.
Afiliação
  • Assenat E; Medical Oncology Department, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.
  • Mineur L; Centre Hospitalier Régional Universitaire (CHU) de Montpellier, Univ. Montpellier, Montpellier, France.
  • Mollevi C; Unité de Cancérologie Digestive Oncologie Radiothérapie, Institut Sainte Catherine, Avignon, France.
  • Lopez-Crapez E; Biometrics Unit, Institut du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
  • Lombard-Bohas C; Translational Research Unit, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
  • Samalin E; Centre Hospitalier Edouard Herriot, Lyon, France.
  • Portales F; Medical Oncology Department, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.
  • Walter T; Medical Oncology Department, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.
  • de Forges H; Centre Hospitalier Edouard Herriot, Lyon, France.
  • Dupuy M; Clinical Research and Innovation Department, Institut du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
  • Boissière-Michot F; Centre Hospitalier Régional Universitaire (CHU) de Montpellier, Univ. Montpellier, Montpellier, France.
  • Ho-Pun-Cheung A; Translational Research Unit, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
  • Ychou M; Translational Research Unit, Institut Régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
  • Mazard T; Medical Oncology Department, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.
Int J Cancer ; 148(3): 682-691, 2021 02 01.
Article em En | MEDLINE | ID: mdl-33405269
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Desoxicitidina / Cloridrato de Erlotinib / Trastuzumab Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Desoxicitidina / Cloridrato de Erlotinib / Trastuzumab Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França País de publicação: Estados Unidos